Multiplexed, high-sensitivity, quantitative immune analysis from limited sample input.
Built on well-established assay formats, MSD® leverages electroluminescent (ECL) detection for multiplexed cytokine measurements, offering distinct advantages over more traditional platforms.
Highly sensitive quantitative data can be generated from serum or plasma samples as small as 25µL, with a large library of customizable single plex and multiplex panels available to support your study’s objectives.
MSD delivers low limits of detection and broad dynamic ranges, providing reliable quantitative data across a wide concentration span. These features can be critical for measuring immune responses in a clinical setting.
CellCarta supports and validates standard multiplex MSD® panels investigating cytokines, chemokines, and inflammation markers.
Alternatively, your team can work with CellCarta to design custom MSD® panels tailored to your specific analyte targets. We can design panels that investigate up to 10 analytes simultaneously, and perform validation for your specific clinical applications.
CellCarta has extensive experience designing and optimizing MSD® assays for use in clinical trials. Notably, our panels are CLIA-certified and have been validated for exploratory and secondary endpoints, ensuring your workflow returns reliable, reproducible results.
MSD delivers low limits of detection and broad dynamic ranges, providing reliable quantitative data across a wide concentration span. These features can be critical for measuring immune responses in a clinical setting.
CellCarta supports and validates standard multiplex MSD® panels investigating cytokines, chemokines, and inflammation markers.
Alternatively, your team can work with CellCarta to design custom MSD® panels tailored to your specific analyte targets. We can design panels that investigate up to 10 analytes simultaneously, and perform validation for your specific clinical applications.
CellCarta has extensive experience designing and optimizing MSD® assays for use in clinical trials. Notably, our panels are CLIA-certified and have been validated for exploratory and secondary endpoints, ensuring your workflow returns reliable, reproducible results.
From vaccine efficacy assessment to GLP/GCLP-validated clinical biomarker screening and measurement, CellCarta’s Meso Scale Discovery services support quantitative immune profiling across the drug development continuum, and measuring of established analytes.
MSD® services that support clinical-grade multiplexing and regulatory-ready data.
Multiplexed by Design
Custom Panel Flexibility
Reliable Results
GLP/GCLP Validated
Low Sample Requirements
In a 96-well or 384-well plate format, CellCarta's MSD® assays can measure up to 10 analytes per well simultaneously. MSD® also offers single plex and up to 40 plex formats that can be customized for your specific cytokines and chemokines of interest. All formats enable high-throughput, cost-effective data generation without a proportional increase in sample volume requirements.
Yes. CellCarta has quantified and characterized assays for use in clinical trials. For example, our proinflammatory MSD® panel has been validated for use as secondary endpoints and is CLIA-certified, enabling deployment in regulated clinical laboratory settings. Multi-analyte MSD assays can also be performed in GLP/GCLP-validated environments to support submission-ready regulatory data packages for clinical development programs.
CellCarta's Meso Scale Discovery assays are typically designed to run on serum or plasma samples. Multiplexed measurements of up to 10 analytes require as little as 25 µL of sample per well, allowing for the preservation of limited and/or precious clinical samples while generating comprehensive immune profile data from a single measurement.